Journal
CHEMISTRY-A EUROPEAN JOURNAL
Volume 25, Issue 1, Pages 43-59Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/chem.201803174
Keywords
Bioconjugation; Cysteine; Maleimide; retro-Michael
Categories
Funding
- Fundacao para a Ciencia e a Tecnologia (FCT) Portugal [SFRH/BPD/102296/2014, PTDC/QEQ-QOR/1434/2014, PTDC/QEQ-MED/5512/2014, PTDC/QEQ-QOR/3644/2014, FEDER-029967, SAICT-PAC/0019/2015, PD/BD/128239/2016, UID/DTP/04138/2013]
- Fundação para a Ciência e a Tecnologia [PTDC/QEQ-MED/5512/2014, PTDC/QEQ-QOR/3644/2014, PTDC/QEQ-QOR/1434/2014, PD/BD/128239/2016, SFRH/BPD/102296/2014] Funding Source: FCT
Ask authors/readers for more resources
Maleimide chemistry stands out in the bioconjugation toolbox by virtue of its synthetic accessibility, excellent reactivity, and practicability. The second-generation of clinically approved antibody-drug conjugates (ADC) and much of the current ADC pipeline in clinical trials contain the maleimide linkage. However, thiosuccinimide linkages are now known to be less robust than once thought, and ergo, are correlated with suboptimal pharmacodynamics, pharmacokinetics, and safety profiles in some ADC constructs. Rational design of novel generations of maleimides and maleimide-type reagents have been reported to address the shortcomings of classical maleimides, allowing for the formation of robust bioconjugate linkages. This review highlights the main strategies for rational reagent design that have allowed irreversible bioconjugations in cysteines, reversible labelling strategies and disulfide re-bridging.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available